The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.
The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.
European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.
Last week's Innovate2006 conference in Zaragoza included a pre-conference tour of the region with an interesting visit of Endesa and one of the largest Spanish windmill farms, located just a few miles north off Zaragoza.
Yet another consultation is under way into the safety of nanotechnology. This time you have an opportunity to give your views on "the use of nanotechnologies in relation to food".
Without access to easy to use analysis tools, patents are becoming an expensive hindrance to many small companies, says Mick McLean, Head of Economics and Public Policy at Scientific Generics.
A team of Danish researchers has devised a method for developing faster silicon computer chips, and is now seeking investment to develop the technique.
Swiss researchers have devised a way to make X-ray imaging much more sensitive – and capable of being incorporated into current medical imaging equipment.
OncoMethylome Sciences is planning to raise funds via an IPO. Its diagnostics can detect early-stage cancer and predict the response to particular cancer drugs.
The controversial proposal for a new European Institute of Technology hit more political turbulence, as the EU’s research commissioner questioned whether it should receive preferential funding.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.